1. Home
  2. TULP vs GRDX Comparison

TULP vs GRDX Comparison

Compare TULP & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TULP

Bloomia Holdings Inc. Common Stock

N/A

Current Price

$3.96

Market Cap

7.3M

ML Signal

N/A

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$2.52

Market Cap

7.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TULP
GRDX
Founded
1990
N/A
Country
United States
United Kingdom
Employees
160
2
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
7.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TULP
GRDX
Price
$3.96
$2.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.3K
98.6K
Earning Date
02-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.61
$1.87
52 Week High
$4.79
$5.30

Technical Indicators

Market Signals
Indicator
TULP
GRDX
Relative Strength Index (RSI) 50.47 55.35
Support Level $3.87 $1.99
Resistance Level $4.08 $2.73
Average True Range (ATR) 0.11 0.25
MACD 0.01 0.02
Stochastic Oscillator 72.71 51.91

Price Performance

Historical Comparison
TULP
GRDX

About TULP Bloomia Holdings Inc. Common Stock

Bloomia Holdings Inc is a specialty ag company focused on making and managing its ag investments in the U.S. and internationally. The Company is the majority owner of Bloomia, one of the largest producers of fresh-cut tulips in the United States.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: